Navigation Links
Neuralstem Fills Key Product Development Position
Date:7/30/2008

FOCUS ON ALS CLINICALS AND DRUG DEVELOPMENT

ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Stem cell company Neuralstem, Inc. (Amex: CUR) announced that Dr. Thomas Hazel will be rejoining the company as Executive Vice President, Research. He will be working with Dr. Karl Johe, Neuralstem's Chairman and Chief Science Officer, to manage the company's upcoming clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease), and complete development of Neuralstem's small molecule neurogenesis compound targeted to treat depression.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Dr. Hazel returns to Neuralstem after a four year stint as Chief Science Officer at Innovative BioSensors, in Maryland. Prior to that, Dr. Hazel worked with Dr. Johe at Neuralstem for four years to develop the company's techniques for isolating and growing human neural stem cells. Before Neuralstem in 1998, Dr. Hazel worked as a Senior Staff Scientist at the National Institute of Health, which he joined after receiving his Ph.D. in Genetics from the University of Illinois.

"Tom has the background to make a substantial contribution the day he arrives," observed Dr. Johe. "I expect this to accelerate our product development cycle."

"Tom's addition to our senior management team will increase its depth, expand the range of partners that we can work with worldwide, and speed up our progress to market," commented Neuralstem CEO, Richard Garr. "This is an important hire for us."

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company is currently targeting diseases and injuries of the spinal cord for its first human trials, including ALS and Paraplegia.

The company has also developed neurogenic and neuroprotective small molecule compounds targeted at treating depression. For further information, please visit http://www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended March 31, 2008.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Responds to New StemCells, Inc. Lawsuit
2. Neuralstem Sues StemCells, Inc. Over New Patent
3. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
4. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
5. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
6. Neuralstem Shares Accepted for Trading on Amex(R)
7. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
8. Instrumentation Laboratory Announces Contract for Multi-Parameter Testing Products with Broadlane
9. Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch
10. Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry
11. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today ... based Phase 1 trial with severe kidney ... reducing inflamed protein biomarkers in patients with severe kidney ... this is the first time in medical history that ... between epigenetic regulation and its potential for positive disease ...
(Date:1/23/2017)... ... January 23, 2017 , ... CallTower is proud to announce ... of the Year Award winner for 2017. , For three consecutive years, CallTower ... In 2016, CallTower was awarded with the hosted VoIP Excellence award and in 2015, ...
(Date:1/21/2017)... -- Bioptix, Inc. (Nasdaq: BIOP ... 14, 2017 the Board of Directors of the Company ... certain employees associated with the September 2016 acquisition of ... on January 16, 2017 and terminations are expected to ... severance benefits in certain circumstances of up to one ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo Bioworks, ... Gen9, a pioneer in the synthesis and assembly ... expertise in assembling pathway-length synthetic DNA into Ginkgo,s ... capacity in the construction of new organism designs ... "Gen9 was founded to significantly increase ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions ... Identity management products and solutions and a cutting-edge ... today that it is offering seamless, integrated solutions ... security entrance products. The solutions provide IdentyTech,s customers ... secure their facilities from crime and theft. ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
Breaking Biology News(10 mins):